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Decoding and reprogramming fungal iterative
nonribosomal peptide synthetases
Dayu Yu1,2,*, Fuchao Xu2,*, Shuwei Zhang2 & Jixun Zhan2

Nonribosomal peptide synthetases (NRPSs) assemble a large group of structurally and
functionally diverse natural products. While the iterative catalytic mechanism of bacterial
NRPSs is known, it remains unclear how fungal NRPSs create products of desired length. Here
we show that fungal iterative NRPSs adopt an alternate incorporation strategy. Beauvericin
and bassianolide synthetases have the same C1-A1-T1-C2-A2-MT-T2a-T2b-C3 domain
organization. During catalysis, C3 and C2 take turns to incorporate the two biosynthetic
precursors into the growing depsipeptide chain that swings between T1 and T2a/T2b with
C3 cyclizing the chain when it reaches the full length. We reconstruct the total biosynthesis of
beauvericin in vitro by reacting C2 and C3 with two SNAC-linked precursors and present
a domain swapping approach to reprogramming these enzymes for peptides with altered
lengths. These ﬁndings highlight the difference between bacterial and fungal NRPS
mechanisms and provide a framework for the enzymatic synthesis of non-natural
nonribosomal peptides.
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onribosomal peptides (NRPs) represent an important
family of bioactive natural products, such as daptomycin,
penicillin and vancomycin. They are assembled
by nonribosomal peptide synthetases (NRPSs) that consist
of a series of catalytic domains1. Adenylation (A), thiolation
(T) and condensation (C) are essential domains for the formation
and elongation of the peptide chain. Other tailoring domains,
such as methyltransferase (MT), oxidation (Ox) and epimerization (E), contribute to the large structural diversity in natural
NRPs2. Iterative NRPSs generate NRP products with repeated
moieties/monomers3, such as bacterial metabolites enterobactin,
echinomycin and gramicidin, as well as fungal natural products
beauvericin (1), beauvericins A–C (2–4), bassianolide (5), enniatins A–C (6–8) and verticilide (9) (Fig. 1a). These molecules
possess a wide range of biological activities, including antimicrobial, insecticidal, anthelmintic, herbicidal, anti-haptotactic,
anti-cholesterol and anticancer activities3–8. 1–9 are cyclic
oligomers of monomer synthesized from a hydroxycarboxylic
acid and an N-methylated amino acid. For instance, 1 is a cyclic
trimer of a dipeptidol monomer synthesized from N-methyl-Lphenylalanine (N-Me-L-Phe) and D-hydroxyisovaleric acid
(D-Hiv), and 5 is an octadepsipeptide containing four units of
D-Hiv-N-Me-L-Leu (leucine: Leu). However, how fungal iterative
NRPSs are programmed to assemble these compounds is not well
understood.
Beauveria bassiana is a ﬁlamentous fungus known to produce
1–5, and the enzymes responsible for the synthesis of these
compounds have been reported9,10. The beauvericin and
bassianolide synthetases (BbBEAS and BbBSLS) share signiﬁcant
sequence homology (66% identity and 79% similarity) and the
same domain organization (Fig. 1b). In spite of the high sequence
similarity, BbBEAS catalyses recursive head-to-tail condensation of
three dipeptidol monomers, while BbBSLS condenses four
monomers. Thus, these enzymes constitute a promising model to
understand the product elongation and length control mechanism
by fungal iterative NRPSs. The gene sequences of several other
fungal NRPSs with the domain organization of C1-A1-T1-C2-A2MT-T2a-T2b-C3 (Fig. 1b) have also been reported11. The common
architecture of these NRPSs suggests that they share a general
assembly rule.
Previous studies on bacterial iterative NRPSs, such as those
involved in the biosynthesis of tyrocidine and gramicidin S,
revealed that these enzymes use an oligomerization approach for
chain elongation and length control through the C-terminal
thioesterase (TE) domain. They oligomerize a monomer intermediate formed by upstream condensation domains and catalyse
the subsequent head-to-tail cyclization for product release12,13.
However, TE or a homologous domain is absent in fungal
iterative NRPSs such as BbBEAS and BbBSLS. Based on the
conserved signature regions, it was generally proposed that A1 of
BbBEAS and BbBSLS activates D-Hiv, while A2 recognizes L-Phe
and L-Leu, respectively. The activated D-Hiv is transferred to T1,
and MT methylates the A2-activated amino acid4. However, the
roles of several key domains in these fungal NRPSs remain
unknown, including the twin T2 domains and three C domains.
More importantly, the product assembly process by fungal NRPSs
is poorly understood.
In this work, we report that BbBEAS and BbBSLS adopt an
alternate incorporation strategy to assemble the products. The
two precursors, D-Hiv and N-Me-L-Phe/N-Me-L-Leu, are alternately incorporated into the extending depsipeptide chain by
C2 and C3. The C3 domain controls the product length and
cyclizes the full-length depsipeptide chain to form the ﬁnal
products. Products with altered chain lengths are obtained by
swapping the C3 domain, providing a domain swapping approach
to reprogramming these enzymes for new molecules.
2

Results
Puriﬁcation and reconstitution of BbBEAS and BbBSLS. We
have recently expressed BbBEAS and BbBSLS and achieved highyield production of 1–5 (33.8 mg l  1 for 1–4 and 21.7 mg l  1
for 5) in Saccharomyces cerevisiae BJ5464-NpgA14. To decode the
functions of the catalytic domains in BbBEAS (352 kDa) and
BbBSLS (348 kDa), we ﬁrst expressed and puriﬁed these giant
enzymes from S. cerevisiae BJ5464-NpgA. As shown in
Supplementary Fig. 1, both enzymes were expressed in the yeast
and obtained in pure form (0.8 mg l  1 for both BbBEAS and
BbBSLS). Reaction of C-His6-tagged BbBEAS with adenosine
triphosphate (ATP), S-adenosylmethionine (SAM), L-Phe and
D-Hiv yielded 1 (trace i, Fig. 1c), which was conﬁrmed
by electrospray ionisation mass spectrometry (ESI-MS)
(Supplementary Fig. 2), high-resolution electrospray ionisation
mass spectrometry (HR-ESI-MS) (Supplementary Fig. 3) and
a comparison with the authentic sample prepared and fully
characterized in our previous work (trace ii, Fig. 1c)14. Similarly,
BbBSLS was found to synthesize 5 (traces iii and iv, Fig. 1c,
Supplementary Fig. 2 and Supplementary Fig. 4) from L-Leu and
14
D-Hiv . Formation of 1 and 5 allowed direct functional
characterization of BbBEAS and BbBSLS. These results
indicated that both BbBEAS and BbBSLS were functionally
expressed in S. cerevisiae and their catalytic activity can be
reconstituted in vitro, providing a great platform to further study
the catalytic domains in these modular NRPSs.
Roles of the twin T2 domains and the biosynthetic model. Two
possible biosynthetic models were proposed for BbBEAS
and other similar NRPSs: linear (alternate incorporation of
the precursors) and parallel (oligomerization of a monomer
synthesized from the precursors) (Fig. 2a)4. In the linear model,
T1 and T2a/T2b are alternately used for tethering the growing
depsipeptide chain for addition of the D-hydroxycarboxylic acid
and N-Me-L-amino acid units. T2a and T2b have the same
function and only one of them is required. In contrast, in the
parallel model, one of the twin T2 domains is proposed to hold
the synthesized dipeptidol monomer after it is synthesized at the
other T2 domain4. Additional monomers are added to the T2b- or
T2a-linked monomer through oligomerization to form the dimer
and subsequently the trimer (1) or tetramer (5). In this parallel
model, both twin T2 domains are required. Bacterial iterative
NRPSs adopt a product assembly process that is more like the
parallel model in Fig. 2a, except that the growing product chain is
linked to the TE instead of a T domain. To understand what
model is used by fungal iterative NRPSs, it is necessary to reveal
the roles of the twin T2 domains in BbBEAS and BbBSLS.
Sequence analysis revealed that the twin T2 domains in
both BbBEAS and BbBSLS contain the conserved motif
(I/L)GG(D/H)SL, in which the key serine (Ser or S) residue
serves as the phosphopantetheine attachment site (Supplementary
Fig. 5). We ﬁrst examined how inactivation of T2a and/or T2b
affects the biosynthesis. Mutation of S2591 in T2a to alanine (A)
did not abolish the production of beauvericins (trace i, Fig. 2b),
but the titre (0.7±0.1 mg l  1) calculated from three replicates
was signiﬁcantly lower than that (33.8±1.4 mg l  1) by wild-type
BbBEAS. In contrast, the T2b mutant BbBEAS-S2688A produced
beauvericins (trace ii, Fig. 2b) with a titre of 23.0±1.0 mg l  1.
When both key Ser residues were mutated, no products were
synthesized by BbBEAS-S2591A/S2688A (trace iii, Fig. 2b).
We next tested how removal of the twin T2 domains from
BbBEAS affects beauvericin biosynthesis using a dissection and
co-expression approach. BbBEAS was dissected at different
positions and the fragments were functionally expressed in
S. cerevisiae BJ5464-NpgA (traces i–iv, Fig. 2c). Using this system,
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Figure 1 | Fungal iterative NRPSs and their products. (a) Representative NRPs (1–9) synthesized by fungal iterative NRPSs. The monomer unit is green
shaded. (b) Domain organization of BbBEAS and BbBSLS. Both modular enzymes have the same architecture of C1-A1-T1-C2-A2-MT-T2a-T2b-C3. To
differentiate these two enzymes, BbBEAS is shown in blue and BbBSLS in red. (c) HPLC analysis of the in vitro reaction of BbBEAS and BbBSLS with ATP,
SAM, D-Hiv and L-amino acid (L-Phe for BbBEAS and L-Leu for BbBSLS).

we removed T2a from BbBEAS by co-expressing C1-A1-T1-C2-A2MT and T2b-C3 in the yeast. Liquid chromatography–mass
spectrometry (LC–MS) analysis revealed that beauvericins were
produced at 5.0±1.2 mg l  1 (trace v, Fig. 2c) in the absence of
T2a. This was validated by the construction of an intact enzyme
BbBEAS-DT2a, which produced beauvericins at 0.5±0.1 mg l  1
(trace vi, Fig. 2c), conﬁrming that the dissection and
co-expression approach is effective and reliable. To remove T2b,
C1-A1-T1-C2-A2-MT-T2a and standalone C3 were co-expressed in
the yeast, yielding 1–4 at 13.0±3.9 mg l  1 (trace vii, Fig. 2c).
When both T2 domains were removed, no products were detected
(trace viii, Fig. 2c). These results were consistent with those
from Ser mutations, which conﬁrmed that only one of the twin
T2 domains is required for beauvericin biosynthesis.
Similarly, we also dissected BbBSLS before and after T2a, and
conﬁrmed that the fragments can be co-expressed in the yeast to
reconstitute bassianolide biosynthesis (traces i and ii, Fig. 2d).
Removal of T2a (trace iii, Fig. 2d) or T2b (trace iv, Fig. 2d) did not
abolish the production of 5, although the titre by the former was
much lower (2.9 mg l  1 versus 10.6 mg l  1). This further
conﬁrmed that T2a plays a major role in the biosynthetic process
as inactivation or removal of this domain signiﬁcantly lowered
the efﬁciency of the product assembly line. By contrast, T2b is less
important in the biosynthetic process and may serve as an
auxiliary T domain to contribute to the overall efﬁciency. Because
the presence of both twin T2 domains is not necessary for the
biosynthesis, the possibility of oligomerization (parallel model) in
chain elongation can be ruled out. Thus, it is concluded that 1–5
are assembled through an alternate incorporation approach
(linear model, Fig. 2a) by the fungal NRPSs.
The condensation activity of the C1 and C2 domains. Another
mystery of BbBEAS and BbBSLS is the unknown roles of the three

C domains in the biosynthetic process. We analysed the
C domains in four reported fungal iterative NRPSs. As shown in
Fig. 3a, the C2 domains of these fungal NRPSs have the conserved
HHxxxDG motif15. It was generally believed that the second
histidine (H) in this motif serves as a general base for the
condensation in most NRPSs, while aspartic acid (D) plays
an important role in the structure of C domains16,17. The ﬁrst
H residue in this motif is not highly conserved, as some
C domains such as the C3 domains shown in Fig. 3a have an S at
this position. The exact function of the G residue in this motif is
not clear. Compared to C2 and C3, the C1 domains of these fungal
NRPSs are more divergent and C1(BbBEAS) does not have the
essential H residue. As the C-terminal condensation domain,
C3 is likely involved in the ﬁnal cyclization and concomitant
release of the peptide chain from the end of the NRPS assembly
lines. The remaining two condensation domains, C1 and C2, are
possibly responsible for forming the ester and amide bonds in
the product assembly line, respectively. We ﬁrst tested the
condensation activity of C2. C2(BbBEAS) was overexpressed and
puriﬁed from E. coli BL21(DE3) (Supplementary Fig. 6), and
reacted with D-Hiv-SNAC (S1) (SNAC: N-acetylcysteamine)18
and N-Me-L-Phe-SNAC (S2). As shown in Fig. 3b, D-Hiv-N-MeL-Phe-SNAC
(S3) was synthesized by C2(BbBEAS), and
then spontaneously cyclized to form cyclo-D-Hiv-N-Me-L-Phe
(10, Fig. 3b). In contrast, this domain could not form an ester
bond as the reaction of S1 and (D-Hiv-N-Me-L-Phe)2-SNAC (S4)
with C2(BbBEAS) did not yield any products (Supplementary
Fig. 7). Consequently, the role of C2 was determined to be
forming the amide bond in the assembly process of NRPs.
We next attempted to understand whether C1 forms the ester
bond. C1(BbBEAS) was overexpressed and puriﬁed from E. coli
BL21(DE3) (Supplementary Fig. 6). Incubation of C1(BbBEAS) with
S1 þ S2 or S1 þ S4 did not yield any products (Fig. 3c,d). Because
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Figure 2 | Roles of the twin T2 domains in BbBEAS and BbBSLS. (a) Two possible models for the assembly process of 1: linear model (top, with ﬁlled
arrows) and parallel model (bottom, with unﬁlled arrows). The two precursors and the growing depsipeptide chain are tethered to the T domains through
phosphopantetheinyl prosthetic groups. In the linear model, T2a and T2b have the same function of holding the growing depsipeptide chain. (b) HPLC
analysis of the products of mutant enzymes BbBEAS-S2591A, BbBEAS-S2688A and BbBEAS-S2591A/S2688A in S. cerevisiae BJ5464-NpgA. (c) HPLC
analysis of the effect of removal of T2a and/or T2b on beauvericin biosynthesis. (d) HPLC analysis of the effect of removal of T2a and/or T2b on bassianolide
biosynthesis.

C1(BbBEAS) lacks the active site H, we mutated D179 to A and
expressed this mutant enzyme BbBEAS-D179A in S. cerevisiae
BJ5464-NpgA. LC–MS analysis revealed the synthesis of
beauvericins by BbBEAS-D179A (trace i, Fig. 3e) at
24.2±1.0 mg l  1, indicating that the mutation did not affect
the biosynthetic process. Similarly, mutation of H170 and D174
in the conserved motif of C1 of BbBSLS did not interfere with
bassianolide biosynthesis (traces ii and iii, Fig. 3e), indicating that
mutation of these functionally or structurally important residues
does not inﬂuence the biosynthesis of 5. These results
clearly indicate that C1 has no condensation activity. To further
4

probe the role of C1 in beauvericin biosynthesis, we constructed a
truncated version of BbBEAS by removing C1. No beauvericins
were produced by BbBEAS-DC1. Addition of standalone
C1(BbBEAS) into the yeast did not recover beauvericin biosynthesis.
SDS–PAGE analysis revealed that BbBEAS-DC1 (308 kDa) was
not expressed and the attempt to purify His6-tagged BbBEASDC1 using Ni-NTA chromatography from the yeast host failed.
Similarly, BbBSLS-DC1 could not be expressed in the yeast either.
Thus, removal of C1 resulted in unsuccessful expression of the
truncated enzymes, suggesting that the presence of C1 is critical
for the expression of BbBEAS and BbBSLS.
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Figure 3 | Investigation of the condensation activity of C1 and C2. (a) Comparison of the conserved HHxxxDG region in the C domains of four reported
fungal iterative NRPSs. The active site H residues are highlighted. (b) HPLC analysis of the in vitro reaction of C2(BbBEAS) with D-Hiv-SNAC (S1) and
N-Me-L-Phe-SNAC (S2). (c) HPLC analysis of the in vitro reaction of C1(BbBEAS) with S1 and S2. (d) HPLC analysis of the in vitro reaction of C1(BbBEAS) with
S1 and S4. (e) HPLC analysis of the products of C1-mutated BbBEAS and BbBSLS in S. cerevisiae BJ5464-NpgA.

The condensation activity of the C3 domain. To understand how
the ester bond is formed, we next investigated the condensation
activity of C3. We ﬁrst removed this domain to yield a truncated
variant of BbBEAS. Expression of BbBEAS-DC3 yielded no
products (trace i, Fig. 4a). In trans addition of standalone
C3(BbBEAS) into S. cerevisiae BJ5464-NpgA reconstituted the
synthesis of beauvericins (26.5±1.3 mg l  1, trace ii, Fig. 4a). This
suggests that C3 plays an essential role in beauvericin biosynthesis.
We next examined the effect of mutation of the conserved H on
beauvericin biosynthesis. BbBEAS-H2901A failed to produce
beauvericins (traces iii, Fig. 4a), indicating that the condensation
activity of C3 is required for the biosynthetic process.
To gain more insight into the role of C3, C-His6-tagged
BbBEAS-DC3 was puriﬁed from S. cerevisiae BJ5464-NpgA and
reacted with ATP, SAM, D-Hiv and L-Phe. No beauvericins were
detected by LC–MS. Instead, small amounts of 10 and 11 (trace i,
Fig. 4b) were produced, which were respectively identiﬁed as the
cyclic and linear D-Hiv-N-Me-L-Phe based on the ESI-MS
(Supplementary Fig. 2) and NMR (Supplementary Table 1) as
well as a comparison with the chemically prepared standards
(traces ii and iii, Fig. 4b). 10 can be hydrolysed in 0.1 N NaOH to
yield 11. Production of 10 and 11 indicated that the biosynthetic
process stopped after the formation of the monomer. The
same products were observed from the reaction of puriﬁed
C-His6-tagged BbBEAS-H2901A (trace iv, Fig. 4b), conﬁrming
that mutation of H2901 did cause the loss of the condensation
ability of C3.
We also overexpressed and puriﬁed C3(BbBEAS) from E. coli
BL21(DE3) (Supplementary Fig. 6). Co-reaction of C3(BbBEAS) and
BbBEAS-DC3 with necessary components yielded 1 (trace i,
Fig. 4c). (D-Hiv-N-Me-L-Phe)2-D-Hiv-SNAC (S5) was synthesized
from S1 and S4 by standalone C3(BbBEAS), then spontaneously
hydrolysed to form (D-Hiv-N-Me-L-Phe)2-D-Hiv (14, Fig. 4d) that

has a molecular mass of 640 (Supplementary Fig. 2). Addition of
S2 into the reaction system did not produce any extra products
including 1 (Supplementary Fig. 8). Thus, C3 is responsible for
the formation of the ester bond between T1-linked D-Hiv and the
monomer D-Hiv-N-Me-L-Phe or the dimer (D-Hiv-N-Me-L-Phe)2
that is tethered to T2a or T2b.
The same experiments were applied to BbBSLS. BbBSLS-DC3
and BbBSLS-H2861A failed to synthesize 5 (traces i and iii,
Fig. 4e). In trans addition of standalone C3(BbBSLS) recovered
bassianolide biosynthesis (traces ii and iv, Fig. 4e). In vitro
reactions of ATP, SAM, D-Hiv and L-Leu with puriﬁed BbBSLSDC3 (trace i, Fig. 4f) or BbBSLS-H2861A (trace ii, Fig. 4f) did not
yield 5, but the linear (12) and cyclic D-Hiv-N-Me-L-Leu (13)
(traces i–iv, Fig. 4f), respectively. Addition of C3(BbBSLS) into the
reaction system reconstituted bassianolide biosynthesis (trace ii,
Fig. 4c). These results further conﬁrmed that C3 plays an essential
role in forming the ester bond during the biosynthesis of 1–5.
Removal or inactivation of C3 did not affect the functions of the
upstream domains, but stopped the biosynthetic process at the
monomer stage.
Identiﬁcation and reprogramming of chain length control.
With the understanding of the roles of the twin T2 and three
condensation domains, we next attempted to identify the
product-length-controlling domain(s) by constructing a series of
chimeric enzymes. Since module 1 of BbBEAS and BbBSLS are
exchangeable without affecting the product proﬁles19, we tested
the effects of swapping the C-terminal domains on the product
formation. We ﬁrst constructed an enzyme C1-A1-T1-C2-A2MT(BbBEAS)T2a-T2b-C3(BbBSLS). Unlike wild-type BbBEAS (trace i,
Fig. 5a), C1-A1-T1-C2-A2-MT(BbBEAS)T2a-T2b-C3(BbBSLS) did not
synthesize beauvericins, but a new product FX1 (15) (trace ii,
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Figure 4 | Investigation of the ether bond-forming activity of C3. (a) HPLC analysis of the in vivo products of C3-less or C3-mutated BbBEAS in S.
cerevisiae BJ5464-NpgA. (b) HPLC analysis of the in vitro reactions of C3-less or C3-mutated BbBEAS with ATP, SAM, D-Hiv and L-Phe. (c) HPLC analysis
of the in vitro reconstitution of the biosynthesis of 1 and 5 by the co-reactions of C3-less NRPS and standalone C3 with ATP, SAM, D-Hiv and L-amino acid
(L-Phe for BbBEAS and L-Leu for BbBSLS). (d) HPLC analysis of the in vitro reaction of C3(BbBEAS) with D-Hiv-SNAC (S1) and (D-Hiv-N-Me-L-Phe)2-SNAC
(S4). (e) HPLC analysis of the in vivo products of C3-less or C3-mutated BbBSLS in S. cerevisiae BJ5464-NpgA. (f) HPLC analysis of the in vitro reactions of
C3-less or C3-mutated BbBSLS with ATP, SAM, D-Hiv and L-Leu.

Fig. 5a) with a molecular mass of 1,044 (Supplementary Fig. 2)
at 3.2±0.6 mg l  1. The molecular formula of 15 was determined
to be C60H76N4O12 by HR-ESI-MS (Supplementary Fig. 9).
The structure was established as a cyclic tetramer (Fig. 5b)
based on the one-dimensional (Supplementary Table 1) and
two-dimensional NMR data (Supplementary Fig. 10). This was
further conﬁrmed by chemical hydrolysis of 15 in 0.1 N NaOH,
which yielded the monomer 11 (Supplementary Fig. 11). We
then made C1-A1-T1-C2-A2-MT-T2a(BbBEAS)-T2b-C3(BbBSLS) and
C1-A1-T1-C2-A2-MT-T2a-T2b(BbBEAS)-C3(BbBSLS). Both enzymes
produced 15 as the sole product (traces iii and iv, Fig. 5a).
These results revealed that replacement of C3(BbBEAS) with
C3(BbBSLS) is sufﬁcient to reprogramme chain length control in
BbBEAS. The same results were obtained for BbBSLS (traces i–iv,
6

Fig. 5c). C1-A1-T1-C2-A2-MT-T2a-T2b(BbBSLS)-C3(BbBEAS) generated 8 (Supplementary Fig. 12) as the only product. Therefore,
C3 was unambiguously identiﬁed as the chain-length-controlling
domain.
C-terminal TE, R, Cy or C is often involved in the cyclization
and concomitant release of the peptide chain from the end of the
NRPS assembly lines20. Since no TE, Cy or R domains are present
in BbBEAS and BbBSLS, we considered that C1 and C3 might be
involved in the macrocyclization. To probe the cyclization activity
and speciﬁcity of C3, three depsipeptidyl-SNACs that mimic the
linear monomer, dimer and trimer intermediates tethered to
T2a or T2b were reacted with C3(BbBEAS). S3 is unstable and can
undergo quick spontaneous cyclization to yield 10 in the reaction
buffer (traces i and ii, Fig. 5d). Addition of C3(BbBEAS) into the
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Figure 5 | Identiﬁcation and reprogramming of chain length control. (a) HPLC analysis of the products of wild-type BbBEAS and its engineered versions
in S. cerevisiae BJ5464-NpgA. (b) Structure of the new tetrameric product FX1 (15) generated by reprogramming BbBEAS. (c) HPLC analysis of the products
of wild-type BbBSLS and its engineered versions in S. cerevisiae BJ5464-NpgA. (d) HPLC analysis of the in vitro reactions of depsipeptidyl-SNACs with
C3(BbBEAS). Three SNAC derivatives including D-Hiv-N-Me-L-Phe-SNAC (S3), (D-Hiv-N-Me-L-Phe)2-SNAC (S4) and (D-Hiv-N-Me-L-Phe)3-SNAC (S6) were
used to mimic the intermediates in beauvericin biosynthesis.

system did not cause observable changes in the formation rate of
10 (trace iii, Fig. 5d). The dimer substrate S4 is stable in the buffer
(trace iv, Fig. 5d), but was not cyclized by C3(BbBEAS) to yield
16 (trace v, Fig. 5d). The trimer substrate (D-Hiv-N-Me-L-Phe)3SNAC (S6) mimics the full-length intermediate. This substrate
is stable in the reaction buffer (trace vi, Fig. 5d). Incubation
of S6 with C3(BbBEAS) yielded 1 (trace vii, Fig. 5d), while
C3(BbBEAS-H2901A) failed to cyclize it (trace viii, Fig. 5d). The same
reactions were applied to C1(BbBEAS) but no cyclization products
16 and 1 were detected. These in vitro reactions further
conﬁrmed that C3 catalysed the macrocyclization in beauvericin
biosynthesis. Mutation of the active site residue H in C3(BbBEAS) to
A abolished its macrocyclization activity, indicating that this
domain uses the same active site for the condensation and
macrocyclization, both leading to the formation of an ester bond
(intermolecular or intramolecular) between the carboxyl of L-Phe
and hydroxyl of D-Hiv. Moreover, C3 only cyclizes the mature
depsipeptide intermediate. This property is critical for chain
length control, which also explains why 10 and 16 are not
produced by the beauvericin-producing strain B. bassiana and the
yeast strain that expresses BbBEAS.
In vitro total biosynthesis of 1 using the C2 and C3 domains.
Our results revealed that C2 and C3 work collaboratively to
generate a linear full-length intermediate that is subsequently

cyclized and released by C3. We next attempted to use these two
domains for in vitro total biosynthesis of 1 from the beginning
precursors. To this end, we reacted C2(BbBEAS) and C3(BbBEAS)
with the two mimicking substrates S1 and S2, while the control
contains the same components except the two domains
were inactivated. The reactions were subjected to LC–MS
analysis. As shown in Fig. 6a, there is a small product peak at
25.8 min that had a [M þ H] þ peak at m/z 642 (Supplementary
Fig. 2). Extraction of the ion chromatogram at m/z 642 (i, Fig. 6a)
from the negative control (left panel) and the reaction
(right panel) revealed that this product was only formed in the
reaction, which has the same molecular mass and retention time
(Fig. 4d) as S4. The extracted ion chromatogram (EIC) at m/z 784
clearly showed the synthesis of 1 (ii, Fig. 6a). Similarly, EICs at
m/z 262, 641 and 903 indicated the formation of 10 (iii), 14 (iv)
and S6 (v) in the reaction mixture. We further enlarged the
high-performance liquid chromatography (HPLC) traces of the
negative control (i, Fig. 6b), the reaction (ii, Fig. 6b) and
the standard of 1 (iii, Fig. 6b), which clearly revealed that 1 was
synthesized from the two beginning precursors S1 and S2 by the
two isolated domains. Furthermore, the peak of S6 was also
observed, which showed the same retention time as the extracted
ion peak shown in trace v of Fig. 6a. These results indicated
the success of in vitro total biosynthesis of 1 by C2 and C3 and
showed a series of biosynthetic intermediates or their hydrolysed
products.
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Figure 6 | In vitro total biosynthesis of 1 using C2 and C3 domains.
(a) LC–MS analysis of the in vitro reaction of C2(BbBEAS) and C3(BbBEAS) with
S1 and S2. The left panel is the negative control with inactivated C2 and C3,
while the right is the actual reaction. The HPLC traces are shown on the top,
followed by the EICs of the intermediates and ﬁnal product. (i)–(v) are EICs
at m/z 642 (i), 784 (ii), 262 (iii), 641 (iv) and 903 (v), respectively.
(b) Enlarged view of the region of 30.1–34.4 min of the HPLC traces of the
negative control (i), reaction (ii) and the standard of 1 (iii).

Discussion
Fungal NRPs represent an important group of bioactive natural
products. BbBEAS and BbBSLS are two fungal iterative
NRPSs that are involved in the biosynthesis of the anticancer
NRPs 1–5. However, the assembly process of these cyclooligomer
depsipeptides is unclear, largely due to the poorly understood
domains including T2a, T2b, C1, C2 and C3 in these modular
enzymes. We used a combination of enzyme dissection, domain
swapping, site-directed mutagenesis and in vitro enzymatic
reactions to study BbBEAS and BbBSLS. This work elucidates
fungal NRPSs’ chain elongation and length control strategy.
Highly consistent results were obtained from both BbBEAS and
BbBSLS, suggesting that this family of fungal iterative NRPSs
follows a general biosynthetic mechanism, which is different from
the approach used by bacterial iterative NRPSs.
A typical NRPS module contains a C domain, an A domain and
a T domain for chain elongation. Co-existence of two T domains in
module 2 of fungal iterative NRPSs not only represents an
interesting structural feature, but also raises questions about the
roles of these T domains in fungal NRP biosynthesis. There are
several examples of twin carrier proteins in a megasynthase. For
example, it was previously reported that module 6 of the
leinamycin polyketide synthase from Streptomyces atroolivaceus
S-140 contains twin acyl carrier protein (ACP) domains that are
separated by a MT domain. Either is sufﬁcient for the biosynthesis,
and ACP6–2 is preferred21. In our work, we found that T2a plays
8

a major role in the formation of the NRPs. Two possible
biosynthetic models have been previously proposed to explain
the biosynthetic process of fungal NRPs based on how the
depsipeptide chain is elongated and how the twin T2 domains
are involved in the assembly process. We speciﬁcally mutated
the key Ser residue in these T domains that is required for the
40 -phosphopantetheinylation. Inactivation of either T2 domain did
not abolish the formation of the corresponding NRPs, but affected
the yield to different extents. Similar results were observed
when one of the T2 domains was removed, providing solid
evidence against the parallel model (Fig. 2a), which requires the
functions of both T2a and T2b. Thus, it is hypothesized that the
biosynthesis of 1–5 proceeds through the linear model (Fig. 2a).
This was conﬁrmed by the in vitro reactions of C2(BbBEAS) and
C3(BbBEAS), which demonstrated that C2 forms the amide bond and
C3 catalyses the synthesis of the ester bond. Co-reactions
of C2(BbBEAS) and C3(BbBEAS) with D-Hiv-SNAC and N-Me-L-PheSNAC reconstituted the in vitro biosynthesis of 1 with only two
condensation domains. Furthermore, some of the intermediates or
hydrolysis products were observed, including cyclo-D-Hiv-N-Me-LPhe, (D-Hiv-N-Me-L-Phe)2-SNAC, (D-Hiv-N-Me-L-Phe)2-D-Hiv
(hydrolysis product) and (D-Hiv-N-Me-L-Phe)3-SNAC, which
provides direct evidence for the alternate incorporation approach
described in the linear biosynthetic model (Fig. 2a).
C3 is a crucial domain that integrates three functions, including
condensation, chain length control and macrocyclization.
While it acts like normal condensation domains to form the
ester bond in the depsipeptide chain, this domain is actively
involved in chain elongation and catalyses the macrocyclization
of the mature intermediate for product release. It is different from
CT domains in fungal noniterative NRPSs that only perform
cyclization22 and Cy domains that form oxazoline or thiazoline
rings using the D residues in the conserved motif DXXXXD23,24.
Bacterial iterative NRPSs typically use a C-terminal TE domain to
cyclize and release the ﬁnal products. The enterobactin synthetase
is such an enzyme whose TE plays a key role in the
oligomerization25. The monomer intermediate is transferred
from the T domain of EntF (C-A-T-TE) to the active site
Ser residue of the TE, which allows the T domain to be used
for the formation of the next monomer. The TE catalyses
the oligomerization and holds the growing peptide chain until it
reaches the full length for macrocyclization. A similar TE was
observed in the tyrocidine12 and gramicidin NRPSs13. It was also
reported that cyclooligomerization can be catalysed through
ATP-dependent condensation reactions by NRPS-independent
siderophore synthetases, such as DesD26, PubC27 and BibC28 that
participate in the biosynthesis of desferrioxamine, putrebactin
and bisucaberin, respectively.
Here we show that fungal iterative NRPSs use a different
strategy for chain elongation and product length control.
Bacterial NRPSs use an oligomerization approach through their
C-terminal TE for product chain elongation. The cyclooligomerization by bacterial iterative NRPSs involves acylation and
deacylation of the active site serine residue of the C-terminal
TE. The monomer intermediate is formed by upstream domains
and transferred from a T domain to the Ser of TE. Additional
units of the monomer are then added to the monomer-O-TE
intermediate to elongate the peptide chain to the full length for
product cyclization and release. Therefore, bacterial iterative
NRPSs oligomerize a monomer unit that is synthesized from the
precursors for chain elongation, and the growing oligomer
intermediate is formed at and always tethered to the TE. In
contrast, fungal iterative NRPSs use an alternate incorporation
approach to extend the peptide chain. The growing depsipeptide
chain in the biosynthesis of 1–5 swings between T1 and the twin
T2 domains. The monomer is not used as a unit for chain
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elongation at all. C3 needs to work with the other condensation
domain (C2) to alternately incorporate the two precursors
(D-Hiv and N-Me-L-Phe or N-Me-L-Leu). Therefore, bacterial
iterative NRPSs adopt a product assembly process that is more
like the parallel model in Fig. 2a, while fungal iterative NRPSs use
a linear biosynthetic route.
In the linear model (Fig. 2a), C3(BbBEAS) forms an ester bond
between T1-tethered D-Hiv and T2a- or T2b-tethered D-Hiv-NMe-L-Phe and (D-Hiv-N-Me-L-Phe)2 in beauvericin biosynthesis,
while C2 catalyses the formation of an amide bond between
T2a- or T2b-tethered N-Me-L-Phe and T1-tethered D-Hiv,
D-Hiv-N-Me-L-Phe-D-Hiv
and (D-Hiv-N-Me-L-Phe)2-D-Hiv.
C3(BbBSLS) has the same function except that N-Me-L-Leu is used.
Both C2 and C3 work collaboratively to elongate the depsipeptide
chain. Once C2 catalyses the last condensation step to yield the
full-length depsipeptide chain, C3 acts as a decision maker to
determine and inform the biosynthetic machinery of whether
further elongation is required. For instance, when a hexadepsipeptide intermediate is synthesized, C3(BbBEAS) will shut down the
elongation line and perform the macrocyclization. Instead,
C3(BbBSLS) will continue the elongation to get an octadepsipeptide
intermediate and then conduct the macrocyclization and product
release. When C3(BbBEAS) was substituted for the C3 in BbBSLS,
it continued to condense D-Hiv and the hexadepsipeptide
intermediate (D-Hiv-N-Me-L-Phe)3, and C2(BbBEAS) will continue
to form an additional amide bond to get an octadepsipeptide.
Cyclization of this intermediate yielded the new product 15.
Similarly, substitution of C3(BbBSLS) with its counterpart in
BbBEAS switched BbBSLS from an octadepsipeptide synthetase
to a hexadepsipeptide synthetase and yielded 8. Thus, C2
is ﬂexible and can catalyse extra or fewer condensations according
to the ‘command’ of C3. While C3 is strict with the number
of condensation, it is ﬂexible enough to condense ‘unnatural’
precursors. Consequently, reprogramming of BbBEAS and
BbBSLS can be conveniently and readily achieved by swapping
the C3 domain. Our work thus provides an unprecedented tool
for engineering fungal iterative NRPSs to yield ‘unnatural’
cyclooligomer depsipeptides with varied chain lengths. This work
also presents in vitro total biosynthesis of a fungal NRP using
only two condensation domains.
Methods
Analysis and puriﬁcation of compounds. Compounds were analysed at 210 nm
using an Agilent Ecilpse XDB-C18 column (5 mm, 4.6 mm  250 mm) on an
Agilent 1200 HPLC coupled with an Agilent 6130 single quadrupole mass
spectrometer. High-resolution mass spectrum of FX1 was collected on an Agilent
6210 LCMS. Four HPLC programmes were used. Programme 1 (for Figs 1c and
3c,d and Figs 4b,d,f and 6): 5–90% acetonitrile–water with 0.1% formic acid from 0
to 30 min, 90–100% acetonitrile–water with 0.1% formic acid from 30 to 35 min
and 100% acetonitrile–water with 0.1% formic acid from 35 to 50 min at
1 ml min  1. Programme 2 (for Figs 2b–d and 3e and Figs 4a,c,e and 5a,c):
80–100% acetonitrile–water with 0.1% formic acid over 20 min at a ﬂow rate of
1 ml min  1. Programme 3 (for Fig. 5d): 50–100% acetonitrile–water with
0.1% formic acid over 30 min at 1 ml min  1. Programme 4 (for Fig. 3b): 5–70%
acetonitrile–water with 0.1% formic acid over 40 min at 1 ml min  1. Compound
puriﬁcation was performed on the same HPLC.
Strains and plasmids. E. coli XL1-Blue (Agilent Technologies) was used for
routine cloning and pJET1.2 (Fermentas) was used as the cloning vector. E. coli
cells were grown in Luria-Bertani (LB) medium at 37 °C. When necessary,
50 mg ml  1 ampicillin was added. E. coli BL21(DE3) (Agilent Technologies) cells
were used for expression of C1(BbBEAS), C2(BbBEAS), C3(BbBEAS), C3(BbBEAS-H2901A),
C3(BbBSLS) and MT(BbBEAS). S. cerevisiae BJ5464-NpgA (MATa ura3-52 his3-D200
leu2- D1 trp1 pep4::HIS3 prb1 D1.6R can1 GAL) was obtained from Dr. Nancy Da
Silva at the University of California, Irvine. The strain was maintained on YPD
(10 mg l  1 yeast extract; 20 mg l  1 peptone; 20 mg l  1 dextrose) agar plates at
30 °C and used for expression of BbBEAS, BbBSLS, their mutants or truncated
variants, and co-expression of the dissected fragments. The E. coli/S. cerevisiae
shuttle vectors YEpADH2p-URA3 and YEpADH2p-TRP1 were gifts from
Dr. Yi Tang at the University of California, Los Angeles.

Gene ampliﬁcation and plasmid construction. The gene fragments C3(bbBeas),
bbBeas-DC3, C1(bbBeas), C1(bbBsls), T2aT2bC3(bbBeas), T2bC3(bbBeas), C3(bbBsls),
C1A1T1C2A2MT(bbBeas), bbBeas-DC1, C1A1T1C2A2MTT2a(bbBeas), bbBsls-DC3, bbBslsDC1, C1A1T1C2A2MT(bbBsls), T2aT2bC3(bbBsls), T2bC3(bbBsls) and C1A1T1C2A2MTT2a(bbBsls) were ampliﬁed by PCR from pDY37 or pDY42 (ref. 14) using Phusion
High-Fidelity DNA Polymerase (New England Biolabs) with speciﬁc primers
(Supplementary Table 2). These PCR products were ligated into the cloning vector
pJET1.2 to yield 16 plasmids including pDY83, pDY85, pDY92, pDY93, pDY104,
pDY105, pDY106, pDY108, pDY109, pDY111, pDY112, pDY113, pDY135,
pDY136, pDY137 and pDY138. These plasmids were conﬁrmed by digestion
checks and gene sequencing.
The C3(bbBeas), T2aT2bC3(bbBeas) and T2bC3(bbBeas) inserts were excised from
pDY83, pDY104 and pDY105 with NheI and PmlI and ligated into YEpADH2pURA3 between the same sites to generate pDY87, pDY114 and pDY115,
respectively. The bbBeas-DC1, bbBsls-DC3, bbBsls-DC1, bbBsls-DT2aT2bC3 and
bbBsls-DT2bC3 inserts were excised from pDY109, pDY112, pDY113, pDY135 and
pDY138 with SpeI and PmlI and ligated into YEpADH2p-URA3 between the same
sites to generate pDY117, pDY119, pDY121, pDY150 and pDY141. The bbBeasDC3, bbBsls-C3, bbBeas-DT2aT2bC3, bbBeas-DT2bC3, T2aT2bC3(bbBsls) and T2bC3(bbBsls)
inserts were excised from pDY85, pDY92, pDY93, pDY106, pDY108, pDY111,
pDY136 and pDY137 with NdeI and PmeI and ligated into YEpADH2p-TRP1
between the same sites to yield pDY88, pDY100, pDY101, pDY116, pDY122,
pDY118, pDY140 and pDY139, respectively.
Site-directed mutagenesis in pDY37 and pDY42 that harbour the original
bbBeas and bbBsls genes was carried out to construct the mutant plasmids. The
PCR conditions were as follows: initial activation of the Phusion High-Fidelity
DNA Polymerase for 5 min at 95 °C, followed by 36 cycles of 40 s denaturation at
95 °C, annealing for 40 s at 63 °C and extension for 15.5 min at 65 °C. PCR
products were treated with DpnI (New England Biolabs) for 24 h at 37 °C to
remove the templates, ligated and introduced into E. coli XL1-Blue. Colonies were
subjected to digestion checks and sequencing to conﬁrm the correct mutation.
pDY145 (bbBeas-H2901A), pDY149 (bbBeas-D179A), pDY158 (bbBeas-S2591A)
and pDY162 (bbBeas-S2688A) were made from pDY37, while pDY151
(bbBsls-H170A), pDY152 (bbBsls-H2861A) and pDY161 (bbBsls-D174A) were
made from pDY42. For double mutations, pDY183 (bbBeas-S2591A) was made
from pDY162.
Based on the AscI site in bbBeas, the gene fragments (AscI)bbBeas  DT2a,
(AscI)bbBeas with T2aT2bC3(bbBsls), (AscI)bbBeas with T2bC3(bbBsls) and (AscI)bbBeas
with C3(bbBsls) were ampliﬁed by splicing by overlap extension PCR using pDY37
and pDY42 as the templates. Similarly, (BsrGI)bbBsls with T2aT2bC3(bbBeas),
(BsrGI)bbBsls with T2bC3(bbBeas) and (BsrGI)bbBsls with C3(bbBeas) were ampliﬁed.
These gene fragments were ligated into the cloning vector pJET1.2 to yield seven
plasmids including pDY165, pDY188, pDY189, pDY190, pDY191, pDY192 and
pDY222. They were conﬁrmed by digestion checks and gene sequencing. The
(AscI)bbBeas-DT2a, (AscI)bbBeas with T2aT2bC3(bbBsls), (AscI)bbBeas with
T2bC3(bbBsls) and (AscI)bbBeas with C3(bbBsls) inserts were excised with AscI and PmlI
from the corresponding pJET1.2-derived plasmids and ligated into pDY37 between
the same sites to generate pDY173, pDY201, pDY204 and pDY203, respectively.
The (BsrGI)bbBsls with T2aT2bC3(bbBeas), (BsrGI)bbBsls with T2bC3(bbBeas) and
(BsrGI)bbBsls with C3(bbBeas) inserts were excised with BsrGI and PmlI from the
corresponding pJET1.2-derived plasmids and ligated into pDY42 between the same
sites to generate pDY215, pDY205 and pDY224, respectively.
The gene fragments C1(bbBeas), C2(bbBeas), C3(bbBeas), C3(bbBsls) and MT(bbBeas) were
ampliﬁed by PCR from the genomic DNA of B. bassiana ATCC 7,159 with Phusion
High-Fidelity DNA Polymerase with speciﬁc primers (Supplementary Table 2).
These gene fragments were ligated into the cloning vector pJET1.2 to yield ﬁve
plasmids including pFC1, pFC62, pFC2, pFC9 and pZJ134. The gene fragment
C3(bbBeas-H2901A) was ampliﬁed from pDY145 and ligated into pJET1.2 to yield
pFC44. These plasmids were conﬁrmed by digestion checks and gene sequencing.
The C1(bbBeas), C3(bbBsls) and MT(bbBeas) inserts were excised from pFC1, pFC9 and
pZJ134 with NdeI and BamHI and ligated into pET28a between the same sites to
generate pFC3, pFC11 and pJCZ21, respectively. The C2(bbBeas) insert was excised
from pFC62 with NdeI and HindIII and ligated into pET28a between the same sites
to generate pFC63. The C3(bbBeas) and C3(BbBEAS-H2901A) inserts were excised from
pFC2 and pFC44 with NheI and BamHI and ligated into pET28a between the same
sites to generate pFC4 and pFC46, respectively.
The plasmids constructed in this work are shown in Supplementary Table 3.

Analysis of the products of the engineered yeast strains. The NRPSs were
expressed in S. cerevisiae BJ5464-NpgA. The correct transformants were selected by
autotrophy of uracil and/or tryptophan. Yeast strains harbouring one plasmid were
cultured in 50 ml of SC-Ura (or -Trp) dropout medium (6.7 mg l  1 yeast nitrogen
base; 20 mg l  1 glucose; 0.77 mg l  1 -Ura or 0.74 mg l  1 -Trp dropout
supplement) at 30 °C with shaking at 250 rpm. For co-expression experiments,
-Trp/-Ura dropout was used. After the OD600 value reached 0.6, an equal volume of
YP medium (10 mg l  1 yeast extract; 20 mg l  1 peptone) was added, and the
cultures were maintained under the same conditions for an additional 3 days.
The cultures were then extracted three times with 100 ml of ethyl acetate and
subjected to analysis on an Agilent 1200 HPLC (at 210 nm) coupled with an
Agilent 6130 single quadrupole mass spectrometer. The product titres were
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calculated from three independent experiments based on the standard curves of
puriﬁed compounds.
Protein expression and puriﬁcation. C-terminal His6-tagged BbBEAS, BbBSLS
and their mutants and truncated variants were expressed in S. cerevisiae
BJ5464-NpgA for protein puriﬁcation. For 1 l of yeast culture, the cells were grown
at 25 °C in modiﬁed YPD medium (with appropriate dropout supplement) that
contains 1% dextrose for 72 h. The cells were collected by centrifugation (4,000 rpm
for 20 min), resuspended in 20 ml of lysis buffer (50 mM NaH2PO4, pH 8.0, 0.15 M
NaCl, 10 mM imidazole) and lysed with sonication on ice. Cell debris was removed
by centrifugation (35,000g for 1 h at 4 °C). Two mililitres of Ni-NTA agarose resin
was incubated with the supernatant at 4 °C for 7 h. The mixture was loaded into a
gravity ﬂow column. Buffer A (50 mM Tris-HCl, pH 7.9, 2 mM EDTA, 2 mM DTT)
with increasing concentrations of imidazole was used as washing buffers. Puriﬁed
proteins were concentrated and exchanged into the reaction buffer (50 mM TrisHCl, pH 8.0). The yields of these modular enzymes were B0.8 mg l  1. N-terminal
His6-tagged C1(BbBEAS) (22.5 mg l  1), C2(BbBEAS) (35.1 mg l  1), C3(BbBEAS)
(29.2 mg l  1), C3(BbBEAS-H2901A) (22.1 mg l  1), C3(BbBSLS) (23.6 mg l  1) and
MT(BbBEAS) (23.0 mg l  1) were expressed with the induction of 200 mM isopropyl
b-D-1-thiogalactopyranoside and puriﬁed from E. coli BL21(DE3) strains
harbouring pFC3, pFC63, pFC4, pFC46, pFC11 and pJCZ21, respectively, using
a similar Ni-NTA chromatography method.
Puriﬁcation and structural characterization of 8 and 15. To isolate the two
products from reprogrammed BbBEAS and BbBSLS, the corresponding cultures
were scaled up to 2 l and grown at 30 °C with shaking at 250 rpm for 72 h. The ethyl
acetate extracts were dried under reduced pressure and subjected to MCI column
chromatography, successively eluted with a gradient of methanol-water
(0:100, 20:80, 50:50 and 100:0, v/v). The fractions containing the target compounds
were further separated by HPLC, eluted with a gradient of acetonitrile–water
(80–100% over 20 min) at a ﬂow rate of 1 ml min  1, to yield 8 (10.1 mg) and
15 (2.5 mg). The puriﬁed compounds were identiﬁed based on the spectral data.
Chemical preparation of substrates and intermediate products. Beauvericins
(1–4) and bassianolide (5) were extracted with ethyl acetate from 5 l of fermentation broths of S. cerevisiae BJ5464-NpgA/pDY37 and S. cerevisiae BJ5464-NpgA/
pDY42, respectively. After evaporation of the solvent, the crude extracts were
hydrolysed in 20 ml of acetonitrile–water (1:1) containing 0.1 N NaOH for 48 h at
40 °C with stirring. The resultant hydrolytic products were extracted by ethyl
acetate, loaded on a silica gel 60 open column, and eluted with a gradient of
acetone-hexanes (50, 70 and 100%, v/v) and methanol. The monomer (11 or 12)containing fractions were puriﬁed by HPLC, washed with 40% acetonitrile–water at
a ﬂow rate of 1 ml min  1 to yield 71.2 mg of 11 and 51.6 mg of 12.
A mixture of 1-ethyl-3-(3-dimethyllaminopropyl) carbodiimide hydrochloride
(0.1 mmol) and hydroxybenzotriazole (0.1 mmol) was added into 15 ml of
tetrahydrofuran containing 0.1 mmol 11 or 12. After stirring the resulting mixture
for 1 h at 40 °C, K2CO3 (0.05 mmol) was added, and the reaction was stirred for
overnight at 40 °C. The reaction was then stopped and concentrated by rotary
evaporation. The resultant cyclized products 10 and 13 were puriﬁed by HPLC.
A gradient of acetonitrile–water (5–60% over 30 min) was programmed at a ﬂow
rate of 1 ml min  1 and 17.6 mg of 10 and 12.2 mg of 13 were puriﬁed from the
respective reactions.
To prepare D-Hiv-N-Me-L-Phe-SNAC (S3), 11 (0.1 mmol) and SNAC
(0.12 mmol) were added to 1 ml of dimethylformamide in a 10- ml round ﬂask and
cooled down to 0 °C. The solution was then treated with diphenylphosphorylazide
(0.15 mmol) and triethylamine (0.2 mmol). The reaction mixture was stirred for 3 h
before the reaction was stopped and concentrated by rotary evaporation. The
resultant monomer-SNAC was puriﬁed by HPLC. A gradient of acetonitrile–water
(5–90% over 30 min) was programmed at a ﬂow rate of 1 ml min  1 to yield
7.7 mg of S3. D-Hiv was purchased from Sigma-Aldrich (St Louis, USA), and
(D-Hiv-N-Me-L-Phe)2 and (D-Hiv-N-Me-L-Phe)3 were purchased from the Chinese
Peptide Company (Hangzhou, China), which were used to synthesize D-Hiv-SNAC
(S1), (D-Hiv-N-Me-L-Phe)2-SNAC (S4) and (D-Hiv-N-Me-L-Phe)3-SNAC (S6)
using the same method for S3.
To prepare N-Methyl-L-Phe-SNAC (S2), L-Phe-SNAC was synthesized ﬁrst.
t-Butyloxy carbonyl (Boc)-L-Phe (1 mmol), N,N-dicyclohexylcarbodiimide
(1 mmol) and 1-hydroxybenzotriazole (1 mmol) were dissolved in 15 ml of
triﬂuoroacetic acid (TFA), followed by adding N-acetylcysteamine (1 mmol). After
stirring the resulting solution for 45 min at 25 °C, K2CO3 (0.5 mmol) was added
and the reaction mixture was stirred for an additional 3 h at 25 °C. After ﬁltration,
the solvent was removed in vacuo. The resulting residue was dissolved in ethyl
acetate and washed once with an equal volume of 10% aqueous NaHCO3. The
organic layer was dried by MgSO4, ﬁltered and concentrated in vacuo. The crude
product was subjected to silica gel column chromatography, eluted with 4% (v/v)
MeOH-CHCl3, to afford Boc-L-Phe-SNACs. Boc group was removed by dissolving
Boc-L-Phe-SNAC in 50% TFA/CH2Cl2 and stirring at 25 °C for 1 h. After removing
solvent, the residue was taken up in a minimal volume of CH2Cl2 and precipitated
with ether. The resulting solid was washed twice with ether and dried to afford
L-Phe-SNAC.
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A typical methylation reaction of L-Phe-SNAC (100 ml) consisted of 6.4 mM
MT(BbBEAS), 0.8 mM L-Phe-SNAC and 2.4 mM SAM in 100 mM Tris-HCl buffer
(pH 7.5). The reaction mixtures were incubated at 25 °C for 30 min and then
quenched with MeOH (50 ml). The mixtures were brieﬂy vortexed and centrifuged
at 15,000 rpm for 5 min to remove the precipitated protein before the samples were
injected into LC–MS for analysis. The supernatants were analysed by HPLC under
235 nm, eluted with an increasing gradient of acetonitrile (10–15%) in H2O
containing 0.1% TFA with a ﬂow rate of 1 ml min  1. Puriﬁcation of S2 was carried
out using the same HPLC method.
In vitro enzymatic studies. For a typical in vitro NRPS activity assay, a 400 ml
reaction contained 50 mM Tris-HCl buffer (pH 8.0), 2 mM NRPS (or dissected
fragments), 5 mM ATP, 25 mM MgCl2, 7.5 mM L-Leu or L-Phe, 2.25 mM D-Hiv and
3 mM SAM. After 3 h incubation at 25 °C, the reactions were quenched with
methanol for LC–MS analysis.
To test the condensation activity of C2, S1 (0.3 mM) and S2 (0.3 mM) or S4
(84 mM) were incubated with 30 mM C2 domain in 1 ml of 50 mM Tris-HCl buffer
(pH 7.8) at 25 °C for 12 h.
To test the condensation activity of C1, S1 (0.3 mM) and S2 (0.3 mM) or S4
(84 mM) were incubated with 30 mM C1 domain in 1 ml of 50 mM Tris-HCl buffer
(pH 7.8) at 25 °C for 12 h.
To test the condensation activity of C3, S4 (84 mM), S1 (0.3 mM) and S2
(0.3 mM, when needed) were incubated with 30 mM C3 domain in 1 ml of 50 mM
Tris-HCl buffer (pH 7.8) at 25 °C for 12 h.
To test the macrocyclization activity of C1 and C3, the SNAC substrates S3, S4
or S6 (75 mM) were, respectively, incubated with 30 mM C1 or C3 domain or their
mutants in 100 ml of 50 mM Tris-HCl buffer (pH 7.8) at 25 °C for 4 h.
For in vitro total biosynthesis, S1 (1 mM) and S2 (1 mM) were incubated
with C2 domain (50 mM) and C3 domain (50 mM) in 2 ml of 50 mM Tris-HCl buffer
(pH 7.8) at 25 °C for 12 h.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its Supplementary Information Files. The
GenBank accession numbers of BbBEAS and BbBSLS are ACI30655 and
ACR78148, respectively. All other data supporting the ﬁndings of this study are
available from the corresponding author on reasonable request.
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